gsk
GlaxoSmithKline / Flickr.com
2 August 2013Patents

Section 3(d) strikes again in GSK India patent defeat

India’s Intellectual Property Appeal Board (IPAB) has revoked a patent covering GlaxoSmithKline’s (GSK) breast cancer drug Tykerb, in the latest blow to western pharmaceutical companies in India.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Copyright
23 September 2019   With pendency rates ranging up to four years, India’s patent owners have a range of options to protect their innovations while they wait, explains Joginder Singh of LexOrbis.